This trial is active, not recruiting.

Condition partial epilepsy
Treatments ykp3089, placebo
Phase phase 2
Sponsor SK Life Science
Start date May 2011
End date June 2013
Trial size 222 participants
Trial identifier NCT01397968, YKP3089C013


This study is to evaluate the efficacy of YKP3089 in reducing seizure frequency when compared to baseline in subjects with partial onset seizures not fully controlled despite their treatment with 1 to 3 concomitant anti-epileptic drugs.

Also to evaluate the safety and tolerability of YKP3089.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification efficacy study
Intervention model parallel assignment
Masking double blind (subject, investigator, outcomes assessor)
Primary purpose treatment
Capsule, dose to be titrated
(Placebo Comparator)
Placebo capsule
Placebo capsule

Primary Outcomes

Percent change in seizure frequency per 28 days in the Treatment Period compared to the Baseline in the Intention to Treat (ITT) Population.
time frame: per 28 days during 12 week treatment period

Secondary Outcomes

Responder rate: An analysis of subjects who experience a 50% or greater reduction in seizure frequency in the Treatment Period of the Double-blind Phase.
time frame: 12 weeks

Eligibility Criteria

Male or female participants from 18 years up to 65 years old.

Inclusion Criteria: - Diagnosis of treatment resistant partial epilepsy; - History of epilepsy for at least 2 years; - Have at least 3 simple partial with motor component, complex partial or secondarily generalized seizures per month with no consecutive 21 day seizure free period. - Currently treated on a stable dose of : - 1 - 3 AED's for at least 12 weeks prior to randomization. - VNS will not be counted as AED; however the parameters must remain stable for at least 4 weeks prior to baseline. - Benzodiazepines taken at least once per week for epilepsy, or for anxiety or sleep disorder, will be counted as 1 AED. Therefore only a maximum of two additional approved AEDs will be allowed. Exclusion Criteria: 1. A history of alcoholism, drug abuse, or drug addiction within the past 2 years. 2. Subject has had status epilepticus within past 1 year. 3. Subject has had greater than 2 allergic reactions to an AED or one serious hypersensitivity reaction to an AED. 4. Subjects taking felbamate with less than 18 months continuous exposure. 5. Subjects receiving phenytoin, phenobarbitone or metabolites of these drugs. 6. No active suicidal plan/intent or active suicidal thoughts in the past 6 months. 7. History of suicide attempt in the last 2 years; not more than 1 lifetime suicide attempt. 8. Subject meets criteria for current major depressive episode (within 6 months). 9. Use of intermittent rescue benzodiazepines more than once/month (1-2 doses in a 24-hour period is considered one rescue) in the one month period prior to Visit 1.

Additional Information

Official title A Phase 2 Multicenter, Double-blind, Randomized, Adjunctive, Placebo-controlled Trial With an Open-label Extension to Evaluate the Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset Seizures
Trial information was received from ClinicalTrials.gov and was last updated in September 2016.
Information provided to ClinicalTrials.gov by SK Life Science.